Healthcare Technology Report June 12, 2024
On May 23, 2024, Massachusetts-based Orna ThReNAgade Therapeutics, a competitor RNA biotech business, was acquired by erapeutics. Although the acquisition’s financial details were kept a secret, the goal of this calculated move is to combine and grow the RNA-focused technology of the two businesses. With $300 million in Series A funding, ReNAgade was introduced in 2023 and has made great progress in getting RNA medications into previously unreachable cells and tissues. Named to BioSpace’s NextGen Bio Class of 2024, ReNAgade has shown promising results in delivering RNA to multiple extra-hepatic cells in non-human primate models.
Orna, founded in 2021, has...
Today's Sponsors
Today's Sponsor